MedTrace Logo

Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation

NCT01262729 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-09-23

No results posted yet for this study

Summary

In this clinical trial will be checked, whether 2 hour ventilation with xenon has neuroprotective effects in patients with out of hospital cardiac arrest and successful cardiopulmonary resuscitation

Conditions

  • Efficacy and Safety of Xenon Inhalation
  • Successful Cardiopulmonary Resuscitation
  • Addition to Therapeutical Hypothermia

Interventions

PROCEDURE

therapeutical hypothermia

Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)

DRUG

Xenon Inhalation

Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Michael Fries, PD Dr. med. · Surgical Intensive Care - Adults, University Hospital Aachen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01262729 on ClinicalTrials.gov